Cargando…
Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis
BACKGROUND: Sulfonylurea (SU) is a commonly used antidiabetic drugs effective for type 2 diabetes mellitus. Previous studies have reported that the SU treatment could alter the serum free fatty acid (FFA) concentration in diabetic patients; however, their exact effects remain unknown. AIM: To assess...
Autores principales: | Yu, Ming, Feng, Xiao-Yu, Yao, Shuai, Wang, Chang, Yang, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477688/ https://www.ncbi.nlm.nih.gov/pubmed/36159441 http://dx.doi.org/10.12998/wjcc.v10.i26.9524 |
Ejemplares similares
-
Estimating the effect of sulfonylurea on HbA(1c) in diabetes: a systematic review and meta-analysis
por: Hirst, J. A., et al.
Publicado: (2013) -
Sulfonylurea for the treatment of neonatal diabetes owing to K(ATP)-channel mutations: a systematic review and meta-analysis
por: Zhang, Hongliang, et al.
Publicado: (2017) -
Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis
por: Huang, Yi-Zhou, et al.
Publicado: (2021) -
Novel glucose-lowering drugs for non-alcoholic fatty liver disease
por: Fu, Zuo-Di, et al.
Publicado: (2021) -
Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis
por: Pan, Lu, et al.
Publicado: (2021)